- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02501811
Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF)
March 29, 2021 updated by: Barry R Davis, The University of Texas Health Science Center, Houston
A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF
This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination (Combo), compared to placebo (cell-free Plasmalyte-A medium) as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, placebo-controlled clinical trial designed to evaluate the feasibility, safety, and effect of Combo, MSCs alone, and c-kit+ cells alone compared with placebo as well as each other in subjects with heart failure of ischemic etiology.
Following a successful lead-in phase, a total of one hundred forty-four (144) subjects will be randomized (1:1:1:1) to receive Combo, MSCs, c-kit+ cells, or placebo.
After randomization, baseline imaging, relevant harvest procedures, and study product injection, subjects will be followed up at 1 day, 1 week, 1 month, 3 months, 6 months and 12 months post study product injection.
All subjects will receive study product injection (cells or placebo) using the NOGA® XP Mapping and Navigation System.
Subjects will have delayed-enhanced magnetic resonance imaging (DEMRI) scans to assess scar size and LV function and structure at baseline and at 6 and 12 months post study product administration.
All endpoints will be assessed at the 6 and 12 month visits which will occur 180 ±30 days and 365 ±30 days respectively from the day of study product injection (Day 0).
For the purpose of the endpoint analysis and safety evaluations, the Investigators will utilize an "intention-to-treat" study population, however an as treated analysis will also be conducted.
Study Type
Interventional
Enrollment (Actual)
125
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine (Falk Cardiovascular Research Center)
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida-Department of Medicine
-
Miami, Florida, United States, 33101
- University of Miami-Interdisciplinary Stem Cell Institute
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana Center for Vascular Biology and Medicine
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Minneapolis Heart Institute Foundation
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Heart Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 79 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be ≥ 21 and <80 years of age
- Have documented coronary artery disease (CAD) with evidence of myocardial injury, LV dysfunction, and clinical evidence of HF
- Have a "detectable" area of myocardial injury defined as ≥ 5% LV involvement (infarct volume) and any subendocardial involvement by cMRI
- Have an EF ≤ 40% by cMRI
- Be receiving guideline-driven medical therapy for heart failure at stable and tolerated doses for ≥ 1 month prior to consent. For beta-blockade "stable" is defined as no greater than a 50% reduction in dose or no more than a 100% increase in dose.
- Be a candidate for cardiac catheterization
- Have NYHA class I, II, or III heart failure symptoms
- If a female of childbearing potential, be willing to use one form of birth control for the duration of the study, and undergo a pregnancy test at baseline and within 36 hours prior to injection
Exclusion Criteria:
- Indication for standard-of-care surgery (including valve surgery, placement of left-ventricular assist device, or imminent heart transplantation), coronary artery bypass grafting (CABG) procedure, and/or percutaneous coronary intervention (PCI) for the treatment of ischemic and/or valvular heart disease. Subjects who require or undergo PCI should undergo these procedures a minimum of 3 months in advance of randomization. Subjects who require or undergo CABG should undergo these procedures a minimum of 4 months in advance of randomization. In addition, subjects who develop a need for revascularization following enrollment should undergo revascularization without delay. Indication for imminent heart transplantation is defined as a high likelihood of transplant prior to collection of the 12 month study endpoint. Candidates cannot be UNOS status 1A or 1B, and they must have documented low probability of being transplanted
- Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2) severe (any valve) insufficiency/regurgitation within 12 months of consent
- Aortic stenosis with valve area ≤ 1.5 cm2
- History of ischemic or hemorrhagic stroke within 90 days of consent
- History of a left ventricular remodeling surgical procedure utilizing prosthetic material
Presence of a pacemaker and/or implantable cardioverter-defibrillator (ICD) generator with any of the following limitations/conditions:
- manufactured before the year 2000
- leads implanted < 6 weeks prior to consent
- non-transvenous epicardial, or abandoned leads
- subcutaneous ICDs
- leadless pacemakers
- any other condition that, in the judgment of device-trained staff, would deem an MRI contraindicated
- Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD are not excluded)
- A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent
- Other MRI contraindications (e.g. patient body habitus incompatible with MRI)
- An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular fibrillation or ventricular tachycardia within 30 days of consent
- Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months of consent, or symptomatic Mobitz II or higher degree atrioventricular block without a functioning pacemaker within 3 months of consent
- Presence of LV thrombus
- Evidence of active myocarditis
- Baseline maximal oxygen consumption (VO2 max) greater than 75% of age and gender based predictive values
- Baseline eGFR <35 ml/min/1.73m2
- Blood glucose levels (HbA1c) >10%
- Hematologic abnormality evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet count < 100,000/ul
- Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3 times the upper limit of normal (ULN)
- Coagulopathy (INR ≥ 1.3) not due to a reversible cause (e.g., warfarin and/or Factor Xa inhibitors). Subjects who cannot be withdrawn from anticoagulation will be excluded.
- HIV and/or active hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Allergy to radiographic contrast material that cannot adequately be managed by premedication
- Known history of anaphylactic reaction to penicillin or streptomycin
- Received gene or cell-based therapy from any source within the previous 12 months
- History of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), excluding basal cell carcinoma and cervical carcinoma in situ which have been definitively treated
- Condition that limits lifespan to < 1 year
- History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months
- Participation in an investigational therapeutic or device trial within 30 days of consent
- Cognitive or language barriers that prohibit obtaining informed consent or any study elements
- Pregnancy or lactation or plans to become pregnant in the next 12 months
- Any other condition that, in the judgment of the Investigator or Sponsor, would impair enrollment, study product administration, or follow-up
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mesenchymal Stem Cells (MSC)
Target dose of 150 million MSCs
|
15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
|
Experimental: c-kit+ cells
Target dose of 5 million c-kit+ cells
|
15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
|
Experimental: Combination Cells (MSC and c-kit+ cells)
Target dose of 150 million MSCs and 5 million c-kit+ cells
|
15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
|
Placebo Comparator: Placebo (Plasmalyte A)
Plasmalyte A
|
15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
Time Frame: Baseline to 6 months
|
Change in left ventricular ejection fraction as assessed via cardiac MRI
|
Baseline to 6 months
|
Change From Baseline in Global Strain (HARP MRI)
Time Frame: Baseline to 6 months
|
Change in global circumferential strain as assessed via cardiac MRI
|
Baseline to 6 months
|
Change From Baseline in Regional Strain (HARP MRI)
Time Frame: Baseline to 6 months
|
Change in regional longitudinal strain as assessed via cardiac MRI
|
Baseline to 6 months
|
Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)
Time Frame: Baseline to 6 months
|
Change in left ventricular end diastolic volume index as measured via cardiac MRI
|
Baseline to 6 months
|
Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)
Time Frame: Baseline to 6 months
|
Change in left ventricular end systolic volume index as assessed via cardiac MRI
|
Baseline to 6 months
|
Change From Baseline in Left Ventricular Sphericity Index
Time Frame: Baseline to 6 months
|
Change in left ventricular sphericity as assessed via cardiac MRI.
Sphericity index is the ratio of the long and short axis measurements of the left ventricle.
|
Baseline to 6 months
|
Change From Baseline in Scar Size Percent (DEMRI)
Time Frame: Baseline to 6 months
|
Change in scar size percent as assessed via cardiac MRI
|
Baseline to 6 months
|
Change From Baseline in Scar Tissue Mass (DEMRI)
Time Frame: Baseline to 6 months
|
Change in scar tissue mass as assessed via cardiac MRI
|
Baseline to 6 months
|
Change From Baseline in Maximal Oxygen Consumption (Peak VO2)
Time Frame: Baseline to 6 months
|
Change in maximal oxygen consumption (peak V02) as assessed via treadmill
|
Baseline to 6 months
|
Change From Baseline in Exercise Tolerance (Six Minute Walk Test)
Time Frame: Baseline to 6 months
|
Change in distance walked (in meters) as measured by the 6 minute walk test.
Two walk tests were completed at each endpoint visit (separated by 30 minutes).
The average distance of the two walk tests was used for analysis.
|
Baseline to 6 months
|
Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score
Time Frame: Baseline to 6 months
|
Change in the quality of life summary score as measured by the Minnesota Living with Heart Failure Questionnaire.
Minimum and maximum scores for the scale are 0 and 105 respectively.
Lower scores indicative of better outcomes.
|
Baseline to 6 months
|
Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
Time Frame: Baseline to 6 months
|
Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via laboratory blood draw
|
Baseline to 6 months
|
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Global Strain (HARP MRI)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Regional Strain (HARP MRI)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, 12 months)
|
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, 12 months)
|
Change From Baseline in Left Ventricular Sphericity Index-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Sphericity index is the ratio of the long and short axis measurements of the left ventricle.
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Scar Size Percent (DEMRI)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Two walk tests were completed at each endpoint visit (separated by 30 minutes).
The average distance of the two walk tests was used for analysis.
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Minimum and maximum scores for the scale are 0 and 105 respectively.
Lower scores indicative of better outcomes.
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The 2nd and 3rd set of results represent differences for varying slopes from the interaction model.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory
Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Log transformation used.
The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time).
The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm.
The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.
|
Assessed as a trajectory (baseline, 6 months, and 12 months)
|
Participants With Major Adverse Cardiac Events (MACE)
Time Frame: Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
|
Number of participants with adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization).
|
Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
|
Participants Experiencing Other Significant Clinical Events
Time Frame: Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
|
Number of participants experiencing other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade
|
Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
|
Cumulative Days Alive and Out of Hospital for Heart Failure
Time Frame: Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
|
Days alive and out of hospital during the study evaluation period.
Subjects were allotted a visit window extending 30 days past their anticipated 12-month visit.
Some participants had extended 12-month visit windows due to the COVID-19 pandemic.
|
Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects With Events Between Randomization and Study Product Injection (SPI) That Preclude the Receipt of Product
Time Frame: Randomization to SPI, an average of 14 weeks
|
Number and percent of subjects with events between randomization and study product injection (SPI) that preclude the subject from receiving product.
Reasons include those who did not undergo harvest (n=6; death, subject withdraw, subject changed mind) and those who did not undergo SPI (n=9; death, LVAD placement, episodes of ventricular tachycardia, and cancelled procedures)
|
Randomization to SPI, an average of 14 weeks
|
Subjects Who Have a Failed Bone Marrow Aspiration Procedure
Time Frame: During bone marrow aspiration procedure
|
Number and percent of subjects who do not successfully undergo bone marrow aspiration
|
During bone marrow aspiration procedure
|
Subjects Who Have a Failed Endomyocardial Biopsy Procedure
Time Frame: During endomyocardial biopsy procedure
|
Number and percent of subjects who do not successfully undergo endomyocardial biopsy procedure.
Note only participants who were assigned to MSC+CPC or to CPC groups had endomyocardial biopsy procedures attempted.
|
During endomyocardial biopsy procedure
|
Subject MSC Products Which Failed Release Criteria
Time Frame: Harvest to Study Product Injection Procedure
|
Number and percent of subjects who have MSC products which failed release criteria
|
Harvest to Study Product Injection Procedure
|
Subject CPC Products Which Failed Release Criteria
Time Frame: Harvest to Study Project Injection procedure
|
Number and percent of subjects who have CPC products which failed release criteria
|
Harvest to Study Project Injection procedure
|
Subjects Who Receive Less Than 15 Injections During SPI
Time Frame: During SPI procedure
|
Number and percent of subjects who received less than 15 injections during SPI
|
During SPI procedure
|
Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable
Time Frame: Baseline to 12 months
|
Number and percent of subjects who have at least one cardiac MRI endpoint measure that is uninterpretable due to issues related to the device, including, but not limited to, inability to undergo the procedure
|
Baseline to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, March KL, Murphy MP, Pepine CJ, Simari RD, Skarlatos SI, Traverse JH, Willerson JT, Szady AD, Taylor DA, Vojvodic RW, Yang PC, Moye LA; Cardiovascular Cell Therapy Research Network. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation. 2013 Apr 16;127(15):1630-5. doi: 10.1161/CIRCULATIONAHA.112.000779. No abstract available.
- Nazarian S, Halperin HR. How to perform magnetic resonance imaging on patients with implantable cardiac arrhythmia devices. Heart Rhythm. 2009 Jan;6(1):138-43. doi: 10.1016/j.hrthm.2008.10.021. Epub 2008 Oct 22. No abstract available.
- Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JAC, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moye L, Ebert RF, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure). Circ Res. 2018 Jun 8;122(12):1703-1715. doi: 10.1161/CIRCRESAHA.118.312978. Epub 2018 Apr 27.
- Kato Y, Kizer JR, Ostovaneh MR, Lazar J, Peng Q, van der Geest RJ, Lima JAC, Ambale-Venkatesh B. Extracellular volume-guided late gadolinium enhancement analysis for non-ischemic cardiomyopathy: The Women's Interagency HIV Study. BMC Med Imaging. 2021 Jul 27;21(1):116. doi: 10.1186/s12880-021-00649-6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2015
Primary Completion (Actual)
June 25, 2020
Study Completion (Actual)
July 22, 2020
Study Registration Dates
First Submitted
July 15, 2015
First Submitted That Met QC Criteria
July 15, 2015
First Posted (Estimate)
July 17, 2015
Study Record Updates
Last Update Posted (Actual)
April 26, 2021
Last Update Submitted That Met QC Criteria
March 29, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-SPH-15-0413
- 5UM1HL087318 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Cardiomyopathy
-
Cedars-Sinai Medical CenterWithdrawnIschemic Cardiomyopathy | Chronic Ischemic CardiomyopathyUnited States
-
Celladon CorporationCompletedHeart Failure | Cardiomyopathies | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathyUnited States, United Kingdom, Belgium, Germany, Poland, Israel, Netherlands, Hungary, Denmark, Sweden
-
Rabin Medical CenterUnknownHeart Failure | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathyIsrael
-
Celladon CorporationTerminatedHeart Failure | Cardiomyopathies | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathyUnited States
-
Assistance Publique - Hôpitaux de ParisCelladon CorporationTerminatedIschemic Cardiomyopathy | Non-ischemic Cardiomyopathy | Heart Failure CongestiveFrance
-
University of Cape TownMedtronicSuspendedDilated Cardiomyopathy | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathySouth Africa
-
Duke UniversityCompletedCardiomyopathy (Ischemic or Non-Ischemic)United States
-
Cairo UniversityNot yet recruiting
-
Navy General Hospital, BeijingFirst People's Hospital of Foshan; General Hospital of Armed Police, Beijing; PLA General Hospital, BeijingUnknown
Clinical Trials on Mesenchymal Stem Cells (MSC)
-
Hadassah Medical OrganizationCompleted
-
Hadassah Medical OrganizationCompletedAmyotrophic Lateral Sclerosis
-
University of LiegeTerminated
-
National Institute of Blood and Marrow Transplant...Armed Forces Institute of Regenerative MedicineCompletedSpinal Cord InjuryPakistan
-
Rigshospitalet, DenmarkCompletedChronic Ischemic Heart DiseaseDenmark
-
Dimitrios KarussisCompletedMultiple Sclerosis (MS)Israel
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Masonic Cancer Center, University of MinnesotaRecruiting
-
N.M. WulffraatCompletedGraft-versus-host-diseaseNetherlands
-
Tehran University of Medical SciencesHormozgan University of Medical SciencesUnknownCerebral Palsy, SpasticIran, Islamic Republic of